Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match

Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match
To be or not to be in Medicare? That's the question facing NZX-listed Pacific Edge. (Image: Pacific Edge)
Rebecca Stevenson
The head of listed cancer diagnostics company Pacific Edge says its singular focus on the United States market is not a single point of failure. Pacific Edge’s share price has taken a hammering after it announced earlier this year it could lose access to the US Medicare system after Novitas – which administers Medicare – determined the Dunedin-based company’s products did not meet new thresholds for coverage under the US Social Security Act. On Monday, its shares were again buffeted by negative news when the US...

More Markets

Soft tissue repair company Aroa could unlock $1.6b market
Markets

Soft tissue repair company Aroa could unlock $1.6b market

A transformational year is predicted for Aroa with maiden profit predicted.

Pūkaki mega-lake never seriously considered
Markets

Pūkaki mega-lake never seriously considered

Officials' idea for a giant lake would have cost billions and had serious impacts.

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Graham Skellern 03 Jul 2024
Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.